ADRENOCORTICAL CARCINOMA
TREATMENT
ACC is one of the rarest endocrine malignancies. Understand the standard treatment algorithm โ mitotane, EDP chemotherapy, specialist surgery โ and where Chinese academic centres fill critical access gaps.
analyticsAt a Glance
- check_circleAdrenocortical carcinoma (ACC) is a rare and aggressive adrenal gland cancer
- check_circleMitotane is the main systemic treatment; EDP-M regimen used in advanced disease
- check_circleSurgery is the only curative option and requires specialist endocrine oncology centres
- check_circleClinical trials and second opinions from specialist centres are strongly recommended
Adrenal Cancer Treatment
ACC treatment is determined by stage, resectability, secretory status, and molecular profile. Localised resectable ACC is treated with radical adrenalectomy at specialist centres. Adjuvant mitotane reduces recurrence risk in high-risk disease. Advanced ACC is treated with mitotane plus EDP chemotherapy as first-line standard.
Mitotane: The Cornerstone
Mitotane is an adrenolytic agent selectively toxic to adrenal cortical tissue. FDA and NMPA approved for ACC. Therapeutic drug monitoring (plasma levels 14โ20 mg/L) is essential. Available in China for patients from countries where access is restricted.
EDP Chemotherapy Plus Mitotane
The FIRM-ACT Phase III trial established EDP (etoposide, doxorubicin, cisplatin) plus mitotane as first-line standard for advanced ACC. Overall response rate approximately 23%. Available at Chinese academic centres.
ACC treatment guidelines
Molecular characterisation guides treatment decisions and identifies hereditary risk.
Key Molecular Alterations
IGF2 overexpression in ~90% of ACC. CTNNB1 mutations in ~20โ25%. TP53 germline mutations (Li-Fraumeni) in ~25% of younger patients. ZNRF3 inactivation in ~20%. TMB is generally low, limiting checkpoint immunotherapy.
Germline Testing: Li-Fraumeni
Approximately 25% of ACC patients under 40 carry germline TP53 mutations. Testing is recommended for all ACC under 40 and all paediatric cases. Implications for family surveillance and reproductive decisions.
Checkpoint Immunotherapy for ACC
Pembrolizumab and avelumab have shown modest activity (~5โ15% ORR) in ACC Phase II trials. ACC is generally not highly immunogenic, but a subset with MSI-H status may respond better. Chinese clinical trials evaluate checkpoint combinations for ACC patients who have exhausted chemotherapy options.
Adrenal Surgery Expertise in China
For localised ACC, Chinese academic centres (CAMS, FUSCC, major urology-endocrine units) perform radical adrenalectomy. Open adrenalectomy with wide margins is recommended over laparoscopic approaches for ACC due to capsule disruption risk. Specialist surgical evaluation is available for international patients.
Benefits and Limitations
Benefits of Chinese ACC Access
- Mitotane access for patients from countries where it is unavailable or unaffordable
- EDP combination chemotherapy at competitive cost
- Specialist adrenal surgical expertise at high-volume centres
- Checkpoint immunotherapy trial access for refractory ACC
Limitations
- ACC remains a poor-prognosis cancer โ mitotane response rate ~15โ25%
- EDP plus mitotane produces median OS ~14 months in advanced disease
- Cure is rare in metastatic ACC even with best available treatment
Mitotane Adrenocortical Carcinoma
Consider Chinese academic centre access for ACC treatment in these situations.
Mitotane Access
Advanced ACC requiring mitotane that is not available domestically.
Surgical Evaluation
Locally advanced or recurrent ACC requiring specialist adrenal surgery.
Trial Access
EDP plus mitotane has failed and checkpoint immunotherapy trial access is being evaluated.
Related Rare Cancer Guides
Explore more pages in the Rare Cancer Treatments series.
Frequently Asked Questions
About Adrenocortical Carcinoma
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Need Access to ACC Treatment?
CancerFax connects adrenocortical carcinoma patients with mitotane access, specialist surgical evaluation, and clinical trial opportunities at Chinese academic centres.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.